MESO (MESO) Stock Price & Analysis
MESO (MESO) rose 3.48% to USD 14.28 as of June 10, 2026 at 07:48 UTC, according to Nexqual real-time market data.
MESO last closed at USD 13.8; the session ranged USD 13.88–14.51 on volume of 173,561 shares. Market capitalization is $1.85B, with a 52-week range of USD 9.88–21.5 (NMS). Source: Nexqual, June 10, 2026 at 07:48 UTC.
Key Statistics (as of June 10, 2026 at 07:48 UTC)
| Price | USD 14.28 |
|---|---|
| Change | ▲ 3.48% (up) |
| Previous Close | USD 13.8 |
| Open | USD 14.19 |
| Day Range | USD 13.88 – 14.51 |
| 52-Week Range | USD 9.88 – 21.5 |
| Volume | 173,561 shares |
| Market Cap | $1.85B |
| Exchange | NMS |
Technical Analysis (MESO)
Nexqual's technical model rates MESO "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.19 (neutral) |
| vs SMA50 | Below (USD 15.05) |
| MACD | -0.24 (negative) |
Analyst Ratings (MESO)
Wall Street analysts rate MESO "None" based on 2 analysts, with a mean price target of USD 35 (range USD 35–35), per Nexqual as of June 10, 2026 at 07:48 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 35 |
| High Target | USD 35 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (MESO)
| Revenue Estimate | $47.13M |
|---|
Source: Nexqual, June 10, 2026 at 07:48 UTC.
Financials & Fundamentals (MESO)
| Total Revenue | $65.38M |
|---|---|
| Revenue Growth (YoY) | +1526.80% |
| Gross Margin | -35.53% |
| Operating Margin | -55.16% |
| Profit Margin | -144.33% |
| ROE | -18.22% |
| Debt / Equity | 23.52 |
| Current Ratio | 1.58 |
| Total Cash | $129.97M |
| Total Debt | $135.14M |
| Free Cash Flow | $-69.44M |
Source: Nexqual, June 10, 2026 at 07:48 UTC.
Financial Health Score (MESO)
Nexqual rates MESO's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:48 UTC.
| Growth | Strong — Revenue +203% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $130M cash vs $135M debt |
| Cash Flow | Weak — FCF negative: -$69M, burning cash |
| Efficiency | Critical — ROE -18%, ROA -6.2% |
Ownership (MESO)
| Insider Ownership | +5.05% |
|---|---|
| Institutional Ownership | +2.80% |
| Shares Outstanding | 129.28M |
| Float | 83.38M |
| Short % of Float | +3.24% |
Source: Nexqual, June 10, 2026 at 07:48 UTC.
Leadership (MESO)
MESO is led by Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) (age 68), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director, per Nexqual as of June 10, 2026 at 07:48 UTC.
| Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director | Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) (age 68) |
|---|---|
| Chief Medical Officer & Executive Director | Eric A. Rose (age 74) |
| Chief Financial Officer | James Michael O'Brien (age 59) |
Major Backers & Investors (MESO)
Notable institutional backers of MESO include Morgan Stanley, Goldman Sachs, Susquehanna International Group, LLP, according to Nexqual as of June 10, 2026 at 07:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 0.4% |
| Goldman Sachs | 0.31% |
| Susquehanna International Group, LLP | 0.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.84% |
Source: Nexqual, June 10, 2026 at 07:48 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CAPR | Capricor Therapeutics, Inc. | USD 26.01 | ▼ 2.62% |
| MCRB | Seres Therapeutics, Inc. | USD 6.33 | ▼ 4.52% |
| MGNX | MacroGenics, Inc. | USD 3.91 | ▲ 0% |
| KPTI | Karyopharm Therapeutics Inc. | USD 8.69 | ▼ 4.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:48 UTC. This page is informational and not investment advice.